Creatine Increases Survival and Delays Motor Symptoms in a Transgenic Animal Model of Huntington's Disease

The Mouse Brain in Stereotaxic Coordinates

Paxinos, G. (2001) · Cited by 12,859

A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes

MACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366

mouse brain in stereotaxic coordinates

Franklin, K. B. J., & Paxinos, G. (1997) · Cited by 3,258

Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice

Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., Lawton, M., Trottier, Y., Lehrach, H., Davies, S. W., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81369-0 · Cited by 3,073

Aggregation of Huntingtin in Neuronal Intranuclear Inclusions and Dystrophic Neurites in Brain

DiFiglia, M., Sapp, E., Chase, K. O., Davies, S. W., Bates, G. P., Vonsattel, J. P., & Aronin, N. (1997) · Science · doi:10.1126/science.277.5334.1990 · Cited by 2,439

Intracellular compartmentation, structure and function of creatine kinase isoenzymes in tissues with high and fluctuating energy demands: the “phosphocreatine circuit” for cellular energy homeostasis

Wallimann, T., Wyss, M., Brdiczka, D., Nicolay, K., & Eppenberger, H. M. (1992) · Biochemical Journal · doi:10.1042/bj2810021 · Cited by 2,011

The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease

Andrew, S. E., Goldberg, Y. P., Kremer, B. P. H., Telenius, H., Theilmann, J., Adam, S., Starr, E. M., Squitieri, F., Lin, B., Kalchman, M. A., et al. (1993) · Nature Genetics · doi:10.1038/ng0893-398 · Cited by 1,135

Trinucleotide repeat length instability and age of onset in Huntington's disease

Duyao, M., Ambrose, C., Myers, R., Novelletto, A., Persichetti, F., Frontali, M., Folstein, S., Ross, C., Franz, M., Abbott, M., et al. (1993) · Nature Genetics · doi:10.1038/ng0893-387 · Cited by 1,089

Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease

Chen, M., Ona, V. O., Li, M., Ferrante, R. J., Fink, K., Zhu, S., Bian, J., Guo, L., Farrell, L. A., Hersch, S. M., et al. (2000) · Nature Medicine · doi:10.1038/77528 · Cited by 1,060

Nuclear and Neuropil Aggregates in Huntington’s Disease: Relationship to Neuropathology

Gutekunst, C.-A., Li, S.-H., Yi, H., Mulroy, J. S., Kuemmerle, S., Jones, R., Rye, D., Ferrante, R. J., Hersch, S. M., & Li, X.-J. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-07-02522.1999 · Cited by 914

Development of novel therapies for Huntington's disease: hope and challenge1

Qin, Z., Wang, J., & Gu, Z. (2005) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2005.00520.x · Cited by 16

Endothelial Dysfunction in Huntington’s Disease: Pathophysiology and Therapeutic Implications

Hu, N., Chen, Z., Zhao, X., Peng, X., Wu, Y. S., Yang, K., & Sun, T. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26041432 · Cited by 15

Creatine protects against 3-nitropropionic acid-induced cell death in murine corticostriatal slice cultures

Vis, J. C., Huizen, R. D. B.-V., Verbeek, M. M., de Waal, R. M. W., ten Donkelaar, H. J., & Kremer, B. H. P. H. (2004) · Brain Research · doi:10.1016/j.brainres.2004.06.087 · Cited by 14

Creatine and neurotrophin-4/5 promote survival of nitric oxide synthase-expressing interneurons in striatal cultures

Ducray, A., Kipfer, S., Huber, A. W., Andres, R. H., Seiler, R. W., Schlattner, U., Wallimann, T., & Widmer, H. R. (2005) · Neuroscience Letters · doi:10.1016/j.neulet.2005.10.051 · Cited by 13

The Biochemistry of Creatine

Turner, C. E., & Gant, N. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-401688-0.00007-0 · Cited by 13

The potential role of creatine supplementation in neurodegenerative diseases

Chang, H., & Leem, Y. (2023) · Physical Activity and Nutrition · doi:10.20463/pan.2023.0037 · Cited by 15

Murine Models of Huntington’s Disease for Evaluating Therapeutics

Kosior, N., & Leavitt, B. R. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7825-0_10 · Cited by 12

Investigations Into Bioenergetic Neuroprotection of Cone Photoreceptors: Relevance to Retinitis Pigmentosa

Narayan, D. S., Chidlow, G., Wood, J. P. M., & Casson, R. J. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.01234 · Cited by 12

Huntington Disease

Wagner, L. A., Menalled, L., Goumeniouk, A. D., Brunner, D., & Leavitt, B. R. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-373861-5.00018-7 · Cited by 12

Neuroprotective therapy for Huntington’s disease: new prospects and challenges

Hersch, S. M., & Rosas, H. D. (2001) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.1.1.111 · Cited by 12

Cytotoxicity models of Huntington’s disease and relevance of hormetic mechanisms: A critical assessment of experimental approaches and strategies

Calabrese, E. J., Bhatia, T. N., Calabrese, V., Dhawan, G., Giordano, J., Hanekamp, Y. N., Kapoor, R., Kozumbo, W. J., & Leak, R. K. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104371 · Cited by 12

Beneficial behavioral effects of chronic cerebral dopamine neurotrophic factor (CDNF) infusion in the N171-82Q transgenic model of Huntington’s disease

Stepanova, P., Kumar, D., Cavonius, K., Korpikoski, J., Sirjala, J., Lindholm, D., & Voutilainen, M. (2023) · Scientific Reports · doi:10.1038/s41598-023-28798-4 · Cited by 5

Intranasal Creatine Administration Increases Brain Creatine Level and Improves Barnes Maze Performance in Rats.

Chen, K., & Hu, X. (2023) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2023.110703 · Cited by 10

Mitochondria in neurodegeneration

Beal, M. F. (2002) · Springer eBooks · doi:10.1007/978-2-8178-0929-8_3 · Cited by 10

Nutraceuticals and Other Natural Products in Parkinson’s Disease Therapy

Mythri, R. B., Joshi, A. K. R., & Bharath, M. M. S. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-411462-3.00044-8 · Cited by 9

Juvenile and adult expression of polyglutamine expanded huntingtin produce distinct aggregate distributions in Drosophila muscle

Barwell, T., Raina, S., Page, A., MacCharles, H., & Seroude, L. (2023) · Human Molecular Genetics · doi:10.1093/hmg/ddad098 · Cited by 8

Newly Synthesized Creatine Derivatives as Potential Neuroprotective and Antioxidant Agents on In Vitro Models of Parkinson’s Disease

Kostadinova, I., Kondeva-Burdina, M., Marinov, L., Vezenkov, L., & Simeonova, R. (2023) · Life · doi:10.3390/life13010139 · Cited by 8

Trinucleotide Repeat Protocols

(2013) · Methods in molecular biology · doi:10.1007/978-1-62703-411-1 · Cited by 8

A Rapid Neurobehavioral Assessment Reveals that FK506 Delays Symptom Onset in R6/2 Huntington's Disease Mice

Ditzler, S. H., Stoeck, J., LeBlanc, M., Kooperberg, C. L., Hansen, S. J., & Olson, J. M. (2003) · Cited by 8

Analysis of Nonmotor Features in Murine Models of Huntington Disease

Baldo, B., & Petersén, Å. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-405195-9.00035-4 · Cited by 7

Calorie Restriction, Longevity and Cognitive Function

Hanjani, N. A., & Vafa, M. R. (2016) · Nutrition and Food Sciences Research · doi:10.18869/acadpub.nfsr.3.1.1 · Cited by 6

Dianas farmacológicas en las enfermedades neurodegenerativas

Segura, T., Galindo, M. F., Rallo, B., Callejo, V. C., & Bueso, J. J. (2003) · Revista de Neurología · doi:10.33588/rn.3611.2003230 · Cited by 7

Mitochondrial VDAC and Its Complexes

Brdiczka, D. G. (2007) · Wiley eBooks · doi:10.1002/9783527621095.ch6 · Cited by 8

Excitotoxicity in amyotrophic lateral sclerosis: a key pathogenic mechanism

Silva-Hucha, S., Hernández, R. G., Baena-López, D., de Sevilla, M. E. F., Paradas, C., & Morcuende, S. (2026) · Brain Communications · doi:10.1093/braincomms/fcag098 · Cited by 7

Recent Advances in the Synthesis of Antioxidant Derivatives: Pharmacological Insights for Neurological Disorders

Singh, K., Gupta, J. K., Sethi, P., Mathew, S., Bhatt, A., Sharma, M. C., Saha, S., Khan, S., & Kumar, S. (2024) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266305736240725052825 · Cited by 6

Neuroprotective Potential of Creatine. Hidden Resources of Its Therapeutic and Preventive Use

Нерсесова, Л. С., Petrosyan, M. S., & Arutjunyan, A. V. (2022) · Neurochemical Journal · doi:10.1134/s1819712422010093 · Cited by 7

Evidence suggesting creatine as a new central neurotransmitter: presence in synaptic vesicles, release upon stimulation, effects on cortical neurons and uptake into synaptosomes and synaptic vesiclesPreprint

Bian, X., Zhu, J., Jia, X., Liang, W., Yu, S., & Rao, Y. (2023) · eLife · doi:10.7554/elife.89317.1 · Cited by 7

Therapeutic strategies for Huntington’s disease: current approaches and future direction

Gulzar, M., Kauser, S., Khan, S., Adnan, M., & Hassan, M. I. (2025) · Neurodegenerative Disease Management · doi:10.1080/17582024.2025.2552593 · Cited by 5

Fueling the Firefighter and Tactical Athlete with Creatine: A Narrative Review of a Key Nutrient for Public Safety

Gonzalez, D. E., Forbes, S. C., Zapp, A., Jagim, A. R., Luedke, J. A., Dickerson, B. L., Root, A., Gil, A. C., Johnson, S. E., Coles, M. E., et al. (2024) · Nutrients · doi:10.3390/nu16193285 · Cited by 6

Breaking Barriers in Huntington’s Disease Therapy: Focused Ultrasound for Targeted Drug Delivery

Helal, M. M., Ibrahim, A., Beddor, A., & Kashbour, M. O. (2025) · Neurochemical Research · doi:10.1007/s11064-024-04302-w · Cited by 5

Plans for HDBase—a research community website for Huntington's Disease

Goodman, N., McCormick, K. M., Goldowitz, D., Hockly, E., Johnson, C., Kristal, B. S., MacDonald, M. E., Truant, R., & van Beuzekom, M. (2003) · Clinical Neuroscience Research · doi:10.1016/s1566-2772(03)00062-8 · Cited by 5

Concentrations of creatine, creatinine, carnosine, and anserine in bovine longissimus muscle and their correlations with carcass and palatability traits

Liu, Q. (2011) · doi:10.31274/etd-180810-682 · Cited by 5

Clinical and Research Advances in Huntington's Disease

SuttonBrown, M., & Suchowersky, O. (2003) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100003231 · Cited by 5

Huntington’s disease and mitochondrial alterations: emphasis on experimental models

de la Cruz, V. P., Carrillo-Mora, P. U., & Santamarı́a, A. (2010) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-010-9289-4 · Cited by 4

Effect of Creatine Monohydrate Supplementation on Various Hematological and Serum Biochemical Parameters of Male Albino Mice following Neonatal Hypoxia‐Ischemia Encephalopathy

Iqbal, S., Nazir, N., Gillani, Q., Akbar, A., & Iqbal, F. (2013) · The Scientific World JOURNAL · doi:10.1155/2013/286075 · Cited by 4

Creatine Monohydrate

Singh, S., & Dash, A. K. (2009) · Profiles of drug substances, excipients, and related methodology · doi:10.1016/s1871-5125(09)34001-7 · Cited by 4

Disease-Modification in Huntington’s Disease: Moving Away from a Single-Target Approach

Jensen, M. P., & Barker, R. A. (2019) · Journal of Huntington s Disease · doi:10.3233/jhd-180320 · Cited by 4

Mechanisms of Excitotoxicity and Excitoprotection

Mattson, M. P. (2004) · Springer eBooks · doi:10.1007/978-1-4419-8959-8_7 · Cited by 4

Investigational drugs for the management of Huntington’s disease: are we there yet?

Kulkarni, P., & Saxena, U. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.934807 · Cited by 4

Translating therapies for Huntington’s disease from genetic animal models to clinical trials

Hersch, S. M., & Ferrante, R. J. (2004) · Neurotherapeutics · doi:10.1007/bf03206614 · Cited by 4

Combination Supplement Therapy: A New Frontier in Treatment of Neurodegenerative Diseases

Shtilbans, A. (2025) · Journal of Nutrition · doi:10.1016/j.tjnut.2025.07.004 · Cited by 3

Physiological Basis for Creatine Supplementation in Skeletal Muscle and the Central Nervous System

Kraemer, W. J., Beeler, M. K., Post, E. M., Luk, H., Lombard, J. R., Dunn‐Lewis, C., & Volek, J. S. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813922-6.00049-7 · Cited by 3

Trinucleotide-Expansion Diseases

Cooper, A. J. L., & Blass, J. P. (2010) · Advances in neurobiology · doi:10.1007/978-1-4419-7104-3_11 · Cited by 3

3-Nitropropionic acid induces histological and behavioral alterations in adult zebrafish: role of antioxidants on behavioral dysfunctionPreprint

Wiprich, M. T., Vasques, R. D. R., Zaluski, A. B., Bertoncello, K. T., Altenhofen, S., Gusso, D., Rodrigues, G., Sachett, A., Piato, Â., Maito, F. L. D. M., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.04.29.591507 · Cited by 3

Potential Therapeutic Strategies for Neurodegenerative Diseases

Farooqui, A. A. (2010) · Springer eBooks · doi:10.1007/978-1-4419-6652-0_9 · Cited by 2

Manganese and Huntington Disease

Tidball, A. M., Bichell, T. J., & Bowman, A. B. (2014) · Royal Society of Chemistry eBooks · doi:10.1039/9781782622383-00540 · Cited by 2

Therapeutics in Huntington’s Disease

Rosas, H. D., & Koroshetz, W. J. (2002) · Handbook of experimental pharmacology · doi:10.1007/978-3-662-06274-6_17 · Cited by 2

Enfermedad de Huntington: estado del arte

Sepúlveda, C. D. R., & García, N. S. (2014) · Repository Technological University of Pereira (Technological University of Pereira) · Cited by 2

Evidence suggesting creatine as a new central neurotransmitter: presence in synaptic vesicles, release upon stimulation, effects on cortical neurons and uptake into synaptosomes and synaptic vesiclesPreprint

Bian, X., Zhu, J., Jia, X., Liang, W., Yu, S., Li, Z., Zhang, W., & Rao, Y. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.12.22.521565 · Cited by 2

Animal models of Huntington's disease. Pros and cons

Stepanova, P., Voutilainen, M. H., Eriksson, O., & Lindholm, D. (2025) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2025.101149 · Cited by 1

Molecular Pathogenesis and Therapeutic Targets in Huntington's Disease

Bett, J. S., Bates, G. P., & Hockly, E. (2006) · Elsevier eBooks · doi:10.1016/b978-012369462-1/50015-6 · Cited by 1

An Overview of Target Specific Neuro-Protective and Neuro-Restorative Strategies

Al, A., Al, K., Al-, A., Arshaduddin, M., & Tariq, M. (2012) · InTech eBooks · doi:10.5772/34731 · Cited by 1

Enfermedad de Huntington: tratamiento

Gatto, E. M. (2013) · Revista de Neuro-Psiquiatría · doi:10.20453/rnp.v65i3-4.1524 · Cited by 1

Human Genome & Diseases: Review Huntington's disease: from huntingtin function and dysfunction to therapeutic strategies

Borrell-Pagés, M., Zala, D., Humbert, S., & Saudou, F. (2006) · Cited by 1

Chapter Mouse Models for Validating Preclinical Candidates for Huntington’s Disease

Lo, D. C., & Hughes, R. E. (2010) · CRC Press eBooks · doi:10.1201/ebk0849390005-12 · Cited by 1

The Therapeutic Potential and Molecular Mechanisms Underlying the Neuroprotective Effects of Sativex® - A Cannabis-derived Spray

Motamedy, S., Soltani, B., Kameshki, H., Kermani, A. A., Amleshi, R. S., Nazeri, M., & Shabani, M. (2024) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/0113895575285934240123110158 · Cited by 1

Dentatorubral-pallidoluysian atrophy (DRPLA): model for Huntington's disease and other polyglutamine diseases

Ross, C. A., Ellerby, L., Wood, J., & Nucifora, F. C. (2005) · Cambridge University Press eBooks · doi:10.1017/cbo9780511544873.059 · Cited by 1

Creatine supplementation and exercise as possible therapeutic treatments in Parkinson’s Disease: A review

Graham, S. M., Baird, M., & Boyd, G. W. (2014) · Archives of Exercise in Health and Disease · doi:10.5628/aehd.v4i3.169 · Cited by 1

Magnetic resonance spectroscopy of neurodegenerative illness

Jenkins, B. G., Choi, J., & Beal, M. F. (2005) · Cambridge University Press eBooks · doi:10.1017/cbo9780511544873.022 · Cited by 1

Mouse Models of Triplet Repeat Diseases

Bates, G. P., & Hay, D. (2004) · Humana Press eBooks · doi:10.1385/1-59259-804-8:003 · Cited by 1

Identifying new therapeutics for Huntington's disease

Schilling, G., & Borchelt, D. (2003) · Clinical Neuroscience Research · doi:10.1016/s1566-2772(03)00060-4 · Cited by 1

Mitochondrial Bioenergy in Neural Disease: Huntington and ParkinsonPreprint

Tassone, A., Meringolo, M., Bonsi, P., Schirinzi, T., & Martella, G. (2023) · Preprints.org · doi:10.20944/preprints202302.0015.v1

Evidence suggesting creatine as a new central neurotransmitter: presence in synaptic vesicles, release upon stimulation, effects on cortical neurons and uptake into synaptosomes and synaptic vesiclesPreprint

Bian, X., Zhu, J., Jia, X., Liang, W., Yu, S., Li, Z., Zhang, W., & Rao, Y. (2023) · eLife · doi:10.7554/elife.89317.2 · Cited by 1

Intrabodies as Therapeutics for Huntington’s Disease

Southwell, A. L. (2009) · CaltechTHESIS (California Institute of Technology) · doi:10.7907/ddsd-7k09

The Study of Two Strategies for Decreasing Mutant Huntingtin: Degradation by Puromycin Sensitive AminoPeptidase and RNA Interference: A Dissertation

Chaurette, J. (2013) · doi:10.13028/m2930z

THE ROLE OF P53 IN OXIDATIVE STRESS AND POLYGLUTAMINE NEUROTOXICITY

Dunn, J. C. (2003) · UKnowledge (University of Kentucky)

Definiendo la etiopatogénesis del síndrome de deficiencia de creatina cerebral

Alonso, P. A. (2014) · Biblos-e Archivo (Universidad Autónoma de Madrid)

Sports Applications of Creatine

Kreider, R. B. (2009) · Humana Press eBooks · doi:10.1007/978-1-59745-302-8_20

β-cell dysfunction in Huntington's disease

Bacos, K. (2009) · Lund University Publications (Lund University)

Developing a neuroprotective therapy for Parkinson’s and Huntington’s diseases

Kazantsev, A. G. (2007) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.17.2.159

A clinical,pathological and genetic study of a Chinese family with Kennedy disease

Zhao, M., ZHANG, S.-Q., Wang, W., Xu, X., & Ding, S.-J. (2010) · Academic Journal of Second Military Medical University · doi:10.3724/sp.j.1008.2009.01254

Alpha Synuclein Aggregation in a Neurotoxic Model of Parkinson's Disease

Kowall, N. W. (2000) · doi:10.21236/ada393984

Molecular Pathways of Mitochondrial Dysfunction in Neurodegeneration: the Paradigms of Parkinson's and Huntington's Diseases

Rego, A. C., Cardoso, S. M., & Oliveira, C. R. (2007) · Springer eBooks · doi:10.1007/978-0-387-70830-0_9 · Cited by 1

A Genome-Wide RNAi Screen for Modifiers of Polyglutamine-Induced Neurotoxicity in Drosophila

Voßfeldt, H. (2013) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-3767

Bioenergetic Defects and Oxidative Damage in Transgenic Mouse Models of Neurodegenerative Disorders

Browne, S. E. (2003) · Defense Technical Information Center (DTIC) · doi:10.21236/ada419306

Murine Models of Huntington Disease

Sturrock, A., & Leavitt, B. R. (2009) · Future Neurology · doi:10.2217/fnl.09.34

Mechanismen von Exzitotoxizität und Neuroprotektion in hippocampalen Zellen in einem in vitro Modell der Schizophrenie

Möller, H. (2009)

Huntington’s Disease

Raymond, L. A., & Leavitt, B. R. (2005) · Neurological disease and therapy · doi:10.1201/9780849358364.ch16

Cytochrome c oxidase mediates the regulation of mitochondrial function in an in vitro model of Huntington's disease

Singh, S., & Wagner, H. N. (2009) · RWTH Publications (RWTH Aachen)

Creatine

Greenwood, M., Leutholtz, B., & Kreider, R. B. (2004) · CRC Press eBooks · doi:10.1201/9780203507704.ch6

Creatine

Kreider, R. B. (2007) · CRC Press eBooks · doi:10.1201/9781420008500.ch9

Evidence suggesting creatine as a new central neurotransmitter: presence in synaptic vesicles, release upon stimulation, effects on cortical neurons and uptake into synaptosomes and synaptic vesiclesPreprint

Bian, X., Zhu, J., Jia, X., Liang, W., Yu, S., Li, Z., Zhang, W., & Rao, Y. (2023) · eLife · doi:10.7554/elife.89317.3

THE ROLE OF CREATINE IN NEUROLOGICAL DISORDERS: A LITERATURE REVIEW

Omidi, A., Ćwiek, M., Malec, K., Krawiec, B., Zarębski, B., Jadanowski, O., Sójka, J., Szombara, M., Mokrzyński, M., & Szyszka, P. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(47).2025.3722 · Cited by 1

Étude de l'implication potentielle des marqueurs du striatum dans la maladie de Huntington

Galvan, L. (2011) · theses.fr (ABES) · doi:10.70675/ebf9c275z3ce2z474dz8d5az68c2c35df509

A Study of Striatal Markers as Disease Modifiers in Huntington's Disease

Francelle, L. (2014) · theses.fr (ABES) · doi:10.70675/ac372f63z7712z4632z8782z6b71a643add2

Study of vesicular glycolysis in health and Huntington's Disease

Cluskey, M. M. (2021) · theses.fr (ABES) · doi:10.70675/eb022640z9c3cz4467z940dz6b27765c296b

Creatine metabolism regulates trophectoderm formation in early mouse embryos via an energy-cytoskeleton-YAP axis

Chen, X., Pan, B., Qin, J., Wei, Y., Du, K., Ning, A., Sun, T., Wang, C., Zou, S., Su, X., et al. (2026) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2026.113147

3-Nitropropionic acid induces behavioral alterations in adult zebrafish: Role of antioxidants on behavioral dysfunction

Wiprich, M. T., Vasques, R. D. R., Zaluski, A. B., Bertoncello, K. T., Altenhofen, S., Gusso, D., Rodrigues, G., Sachett, A., Piato, Â., Maito, F. L. D. M., et al. (2026) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2026.111840

BindingDB Entry 50025569: A small-molecule therapeutic lead for Huntington's disease: preclinical pharmacology and efficacy of C2-8 in the R6/2 transgenic mouse.

BindingDB (2010) · UC San Diego · doi:10.7270/q2x34x7v

Farmakoterapia zaburzeń ruchowych i objawów neuropsychiatrycznych w chorobie Huntingtona: systematyczny przegląd piśmiennictwa

Sobów, T., & Sławek, J. W. (2007) · Aktualności Neurologiczne

Neuroprotective Effects of Creatine in a Transgenic Mouse Model of Huntington's Disease

Ferrante, R. J., Andreassen, O. A., Jenkins, B. G., Dedeoglu, A., Kuemmerle, S., Kubilus, J. K., Kaddurah-Daouk, R., Hersch, S. M., & Beal, M. F. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-12-04389.2000 · Cited by 522

Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice

Dedeoglu, A., Kubilus, J. K., Yang, L., Ferrante, K. L., Hersch, S. M., Beal, M. F., & Ferrante, A. R. J. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01706.x · Cited by 169

Creatine-supplemented diet extends Purkinje cell survival in spinocerebellar ataxia type 1 transgenic mice but does not prevent the ataxic phenotype

Kaemmerer, W. F., Rodrigues, C. M. P., Steer, C. J., & Low, W. C. (2001) · Neuroscience · doi:10.1016/s0306-4522(01)00017-3 · Cited by 37

A modified gas-liquid chromatographic procedure for the rapid determination of bile acids in biological fluids

Nair, P. P., & Garcia, C. (1969) · Analytical Biochemistry · doi:10.1016/0003-2697(69)90020-7 · Cited by 107

Creatine: prescription for bad genes and a hostile environment?

Mattson, M. P. (2000) · Trends in Neurosciences · doi:10.1016/s0166-2236(00)01697-0 · Cited by 6